SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare tumbles on receiving import alert

18 Feb 2021 Evaluate

Shilpa Medicare is currently trading at Rs. 385.85, down by 40.25 points or 9.45% from its previous closing of Rs. 426.10 on the BSE.

The scrip opened at Rs. 425.00 and has touched a high and low of Rs. 425.60 and Rs. 378.25 respectively. So far 117071 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 692.45 on 11-Aug-2020 and a 52 week low of Rs. 240.30 on 31-Mar-2020.

Last one week high and low of the scrip stood at Rs. 433.00 and Rs. 410.00 respectively. The current market cap of the company is Rs. 3208.49 crore.

The promoters holding in the company stood at 53.25%, while Institutions and Non-Institutions held 19.45% and 27.30% respectively.

Shilpa Medicare has received an Import Alert 66-40 on February 17, 2021, pursuant to the USFDA inspection of the Unit 4, Jadcherla, Telangana facility from February 13 - 20 and February 24-25, 2020.

Three products have been exempted from the Import Alert - Azacitidine for Injection, Cyclophosphamide Capsules and Erlotinib Tablets.

The company is committed to address the concerns raised by the USFDA and will work with the US FDA to resolve these issues at the earliest.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

415.85 4.30 (1.04%)
20-Apr-2026 14:33 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.00
Dr. Reddys Lab 1236.05
Cipla 1232.00
Zydus Lifesciences 936.50
Lupin 2327.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×